<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710252</url>
  </required_header>
  <id_info>
    <org_study_id>TLI_IIS_01_2015</org_study_id>
    <nct_id>NCT03710252</nct_id>
  </id_info>
  <brief_title>A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study</brief_title>
  <acronym>HEARTLAND</acronym>
  <official_title>A Study to Investigate HCV Response Rates in Real World Patients Traditionally Excluded From Clinical Trials: The HEARTLAND Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24
      weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24
      weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.

      The study will enroll chronically infected GT 1 patients who are treatment naïve or who have
      failed a regimen including pegIFN/RBV +/- telaprevir, boceprevir, or simeprevir.

      In addition, up to 20 chronically infected GT1 patients who have traditionally been excluded
      from clinical trials due to mild to moderate renal insufficiency, irrespective of other
      co-morbid conditions including poorly controlled diabetes mellitus, high BMI, HIV infection
      will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a Phase IV, open label, single arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary analysis will be sustained virologic response 12 weeks after the last treatment dose (SVR12) for the all treated population.</measure>
    <time_frame>12 weeks after last treatment</time_frame>
    <description>Primary Analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of baseline resistance variants on SVR12 (subgroups: all RAVs, different classes of RAVs)</measure>
    <time_frame>12 weeks after last treatment</time_frame>
    <description>Secondary Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient reported outcomes via the SF36v2 survey (subgroups: those who achieve SVR12 and those who do not)</measure>
    <time_frame>12 weeks after last treatment</time_frame>
    <description>Secondary Analysis. Comparison between baseline and end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient adherence (subgroups: those who achieve SVR12 and those who do not)</measure>
    <time_frame>12 weeks after last treatment</time_frame>
    <description>Secondary Analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) + databuvir (DSV) +/- ribavirin (RBV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin</intervention_name>
    <description>OMB/PTV/r + DSV +/- RBV</description>
    <arm_group_label>Single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

               -  Patients must have chronic GT 1 HCV infection (GT1a, GT1b or GT1a/1b)

               -  Patient and partner(s) must agree to use acceptable methods of contraception

               -  Patient must be able to read and understand English and/or Spanish

               -  Written informed consent

        Exclusion Criteria:

          -  Currently taking or planning on taking any prohibited medications (see US PI)

               -  Evidence of decompensated liver disease (Child-Pugh B or C) including the
                  presence of clinical ascites, bleeding varices, or hepatic encephalopathy

               -  Abnormal lab values, including:

                    -  Hemoglobin (Hgb) &lt;8 g/dL

                    -  Platelets &lt;25,000 cells/mm3

                    -  Absolute neutrophil count (ANC)&lt;500 cells/mm3

                    -  Bilirubin &gt;3

                    -  INR&gt;2.3 ALT/AST &gt; 10 x ULN

                    -  Serum albumin &lt;2.8

                    -  GFR &lt;30 mL

               -  Alcohol use: &gt;3 drinks per day consistently

               -  Uncontrolled HIV or HBV coinfection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Poordad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Research Corporation</affiliation>
  </overall_official>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

